Henry Khederian
·
September 22, 2025
Benzinga
Tempus AI shares are trading higher Monday morning. The company announced it has received U.S. Food and Drug Administration 510(k) clearance for its RNA-based Tempus xR IVD device.
read more
November 14, 2025
September 5, 2025
September 3, 2025
Bloomberg
August 27, 2025
Fortune
Barchart